Kaléo, Inc. announced that Evzio (naloxone HCl injection) auto-injector is now commercially available for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or CNS depression.
Evzio was approved on April 3, 2014 as the first naloxone product allowing administration by family members or caregivers. Evzio incorporates audio and visual cues to help the user through the injection process.
Naloxone HCl is an opioid antagonist that antagonizes opioid effects by competing for the same receptor sites. Naloxone HCl reverses the effects of opioids, including respiratory depression, sedation, and hypotension. Also, it can reverse the psychotomimetic and dysphoric effects of agonist-antagonists such as pentazocine.
Evzio is available as a 0.4mg strength in a carton containing 2 auto-injectors and a single Trainer.
For more information call (804) 545-6360 or visit Evzio.com.